MedNet.nl: The clinical effect of evolocumab seems to be more pronounced in obese patients (especially if they are obese class 2 or 3). Intensive control of LDL cholesterol should therefore be strongly considered in this population to lower their high cardiovascular risk.
04-09-2024 | Obesity | News